Extended-release calcifediol in stage 3–4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D

Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review

(2021) Oliver Darlington et al.   ADVANCES IN THERAPY

P0901REAL-WORLD ASSESSMENT: CLINICAL EFFECTIVENESS AND SAFETY OF VITAMIN D THERAPIES IN ND-CKD PATIENTS

(2020) Michael J Germain et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease

(2019) S. Geng et al.   OSTEOPOROSIS INTERNATIONAL

Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD)

(2019) Mario Cozzolino et al.   EXPERT OPINION ON PHARMACOTHERAPY

Perceived Health and Quality of Life in Patients With CKD, Including Those With Kidney Failure: Findings From National Surveys in France

(2019) Karine Legrand et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update

(2018) Markus Ketteler et al.   ANNALS OF INTERNAL MEDICINE

The Role of Vitamin D in CKD Stages 3 to 4: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

(2018) Michal L. Melamed et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Skeletal and extra-skeletal actions of vitamin D: Current evidence and outstanding questions

(2018) Roger Bouillon et al.   ENDOCRINE REVIEWS

Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?

(2017) Nigel D Toussaint et al.   NEPHROLOGY

Vitamin D in Chronic Kidney Disease and Dialysis Patients

(2017) Guillaume Jean et al.   Nutrients

Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease

(2017) Andrea Galassi et al.   Expert Review of Clinical Pharmacology

KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)

(2017)   Kidney International Supplements

Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease

(2016) Stuart M. Sprague et al.   AMERICAN JOURNAL OF NEPHROLOGY

Con: Nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease

(2016) Rajiv Agarwal et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis

(2016) Nathan R. Hill et al.   PLoS One

Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study

(2015) Maurizio Gallieni et al.   JOURNAL OF NEPHROLOGY

Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low

(2015) Jennifer L. Ennis et al.   JOURNAL OF NEPHROLOGY

Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation

(2015) Martin Petkovich et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: A systematic review and meta-analysis

(2015) Xiao-Hua Li et al.   NEPHROLOGY

Modified-Release Calcifediol Effectively Controls Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney Disease

(2015) Stuart M. Sprague et al.   AMERICAN JOURNAL OF NEPHROLOGY

Dietary Vitamin D and Its Metabolites Non-Genomically Stabilize the Endothelium

(2015) Christopher C. Gibson et al.   PLoS One

25-Hydroxyvitamin D Testing and Supplementation in CKD: An NKF-KDOQI Controversies Report

(2014) Holly Kramer et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients

(2014) Sylvie Dusilová-Sulková et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial

(2012) Jessica A Alvarez et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Vitamin D in chronic kidney disease

(2011) Adriana Dusso et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM

Secondary Hyperparathyroidism: Pathogenesis, Disease Progression, and Therapeutic Options

(2011) J. Cunningham et al.   Clinical Journal of the American Society of Nephrology

CYP24A1 and kidney disease

(2011) Martin Petkovich et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline

(2011) Michael F. Holick et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Reduced Hepatic Synthesis of Calcidiol in Uremia

(2010) J. Michaud et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Foreword

(2009) Kai-Uwe Eckardt et al.   KIDNEY INTERNATIONAL

Hypovitaminosis D in Chronic Kidney Disease

(2008) R. Mehrotra et al.   Clinical Journal of the American Society of Nephrology

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism

(2008) Mario Cozzolino et al.   EXPERT OPINION ON PHARMACOTHERAPY